



(51) International Patent Classification:
C07K 16/28 (2006.01)

(21) International Application Number:
PCT/US2022/026131

(22) International Filing Date:
25 April 2022 (25.04.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/179,799 26 April 2021 (26.04.2021) US
63/287,655 09 December 2021 (09.12.2021) US

(71) Applicants: **MEMORIAL SLOAN-KETTERING CANCER CENTER** [US/US]; 1275 York Avenue, New York, NY 10065 (US). **SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH** [US/US]; 1275 York Avenue, New York, NY 10065 (US). **MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES** [US/US]; 1275 York Avenue, New York, NY 10065 (US). **MILLENNIUM PHARMACEUTICALS, INC.** [US/US]; 40 Landsdowne Street, Cambridge, MA 02139 (US).

(72) Inventors: **SADELAIN, Michel**; 15 West 84th St., Apt. 2C, New York, NY 10024 (US). **HAUBNER, Sascha P.**; 120 East 30th Street, Apt. 2, New York, NY 10016 (US). **MANSILLA-SOTO, Jorge**; 72-72 112th Street, Apt. 3A, Forrest Hills, NY 11375 (US). **SHAPIRO, Gary**; 40 Landsdowne Street, Cambridge, MA 02139 (US). **HE, Xingyue**; 40 Landsdowne Street, Cambridge, MA 02139 (US).

(74) Agent: **LENDARIS, Steven P.** et al.; Baker Botts LLP, 30 Rockefeller Plaza, New York, NY 10112-4498 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

(54) Title: CHIMERIC RECEPTORS TARGETING ADGRE2 AND/OR CLEC12A AND USES THEREOF




FIGURE 1A

(57) Abstract: The presently disclosed subject matter provides for chimeric receptors that target ADGRE2 and chimeric receptors that target CLEC12A. The presently disclosed subject matter also provides for cells comprising the ADGRE2-targeted chimeric receptors, cells comprising the CLEC12A-targeted chimeric receptors, and cells comprising the ADGRE2-targeted chimeric receptors and the CLEC12A-targeted chimeric receptors. The presently disclosed subject matter further provides uses of such cells for treating tumors, e.g., AML.

[Continued on next page]

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*
- *with sequence listing part of description (Rule 5.2(a))*